Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

$1.08

DILUTED ADJUSTED INCOME PER COMMON

SHARE $1.18 $0.92

WEIGHTED AVERAGE NUMBER OF COMMON

SHARES OUTSTANDING 68,118 66,931

WEIGHTED AVERAGE NUMBER OF COMMON

SHARES OUTSTANDING-ASSUMING DILUTION 78,920 79,030

Notes to Reconciliation of GAAP Net Income to Adjusted Net Income

(1) To exclude the on-going amortization of acquired intangible assets ($24.0 million in 2008; $22.3 million in 2007), accelerated depreciation related to the CIMA LABS restructuring ($1.6 million in 2008), accelerated depreciation related to the proposed divestiture at the Mitry-Mory facility ($2.9 million in 2008), and the write-off of purchase commitments in excess of estimated requirements ($26.0 million in 2008).

(2) In 2008, to exclude accelerated depreciation related to the proposed divestiture at the Mitry-Mory facility. In 2007, to exclude the recognition of a milestone related to the FDA's acceptance of our NDA filing for TREANDA (bendamustine HCl).

(3) To exclude charges related to the estimated termination payments due to Takeda Pharmaceuticals North America, Inc.

(4) In 2008, to exclude charges related to the settlement of investigations by the Offices of the Attorney General of Connecticut and Massachusetts and estimated relator attorney fees. In 2007, to exclude the reserve established for the minimum liability related to the potential settlement of the investigations by the U.S. Attorney's Office.

(5) To exclude the forgiveness of a mortgage loan by the Pennsylvania Industrial Development Board ("PIDA").

(6) To exclude the accrued interest related to the settlement reached with the U.S. Attorney's Office.

(7) To exclude costs related to the CIMA LABS restructuring announced in January 2008.

(8) To reflect the tax effect of pre-tax adjustments at the applicable tax rates and certain other
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... 27, 2014 The Europe Thermal ... market to provide crucial revenue forecasts. It estimates ... growing at a CAGR of 7.5%, from 2013 ... the Europe Thermal Protective Clothing market report for ... analysis supported by various tables and figures. , ...
(Date:11/27/2014)... First articles published now ... Elsevier , a world-leading provider of scientific, technical ... announce the launch of a new journal: ... The launch of Extreme Mechanics Letters is ... of applied sciences such as micro and nanotechnologies, biotechnologies, ...
(Date:11/26/2014)... NOVEMBER 21, 2014 (PRWEB) November 26, 2014 ... health-oriented communications network, today announced the organization has won ... Rx Club Awards. Digitas Health LifeBrands was honored with ... four other PHCG agencies received eight Awards of Excellence. ... creative aspects of pharmaceutical advertising and promotion. The Awards ...
(Date:11/26/2014)... The North America Thermal Protective Clothing Market report ... of the growth trends and revenue forecasts. It ... 2018, growing at a CAGR of 7.1% from ... of the North America Thermal Protective Clothing Market ... analysis and industry segmentation supported by various tables ...
Breaking Biology Technology:The Europe Thermal Protective Clothing market is estimated to grow up to $577.9 million by 2018 - Report by MicroMarket Monitor 2The Europe Thermal Protective Clothing market is estimated to grow up to $577.9 million by 2018 - Report by MicroMarket Monitor 3Elsevier Announces the Launch of a New Journal: Extreme Mechanics Letters 2Elsevier Announces the Launch of a New Journal: Extreme Mechanics Letters 3Publicis Healthcare Wins 20 Rx Club Awards 2Publicis Healthcare Wins 20 Rx Club Awards 3The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 2The North America Thermal Protective Clothing Market is estimated to grow up to $616.3 million by 2018 - Report by MicroMarket Monitor 3
... ICLL) today announced that the Australian Therapeutic Goods,Administration ... to,prevent Japanese Encephalitis. This final decision step for ... Australian Drug Evaluation,Committee (ADEC) in December 2008. , ... Australian authorities represents the first,regulatory approval for the ...
... Aerolase Corporation, a leading manufacturer of next-generation portable ... sales increased dramatically in 2008 over 2007. The ... market helped to more than offset current economic ... record sales month for Aerolase, and 2008 overall ...
... Jan. 23 Peter T. Wilderotter, president and CEO ... following statement today in response to FDA clearance of ... is an exciting first step for Geron and for ... to advances in medical research. There has been so ...
Cached Biology Technology:Australian Authorities (TGA) First to Grant Final Product Approval for Intercell's Vaccine to Prevent Japanese Encephalitis 2Australian Authorities (TGA) First to Grant Final Product Approval for Intercell's Vaccine to Prevent Japanese Encephalitis 3Australian Authorities (TGA) First to Grant Final Product Approval for Intercell's Vaccine to Prevent Japanese Encephalitis 4Aerolase Reports Strong Sales in 2008 for Portable Aesthetic Lasers 2Aerolase Reports Strong Sales in 2008 for Portable Aesthetic Lasers 3Christopher and Dana Reeve Foundation Response to FDA Clearance of Geron's Clinical Trial 2
(Date:11/21/2014)... Nov. 20, 2014   Atmel® Corporation (NASDAQ: ... (MCU) and touch technology solutions, today launched the industry,s ... with the widest V cc range from 1.7V ... and faster I 2 C bus communication speeds, and ... memory making them ideal for consumer, industrial, computer, and ...
(Date:11/18/2014)...   EyeLock Inc. , a market leader ... USA (Safran), a leading U.S. provider of ... partnership to offer comprehensive biometric identity solutions and ... screening and financial services markets. As ... through a nationwide network of 1,100 IdentoGO® Centers.  ...
(Date:11/10/2014)... U.S. store shelves in early 2010, and people have ... packets can be tossed into a washing machine without ... The convenience, though, has come with risks for young ... Children,s Hospital found that from 2012 through 2013, U.S. ... than 6 years of age swallowing, inhaling, or otherwise ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Study finds laundry detergent pods, serious poisoning risk for children 2
... JOLLA, CA-The neuropeptide corticotropin-releasing factor (CRF) makes cameo appearances ... the opening act in the stress response, jump-starting the ... Salk Institute for Biological Studies have found that CRF ... increases insulin secretion and promotes the division of the ...
... San Diego, CA Current research suggests that the ... a significant proportion of mortality during flu pandemics. The related ... synergism between influenza virus and Haemophilus influenzae ," appears ... of Pathology . Influenza affects between three and five ...
... Spanish . , Food-packaging products made from ... packaging products, according to a chapter written by Agricultural ... book, "Dairy-Derived Ingredients: Food and Nutraceutical Uses." ... of contributors and published by London-based Woodhead Publishing in ...
Cached Biology News:Stress peptide and receptor may have role in diabetes 2Stress peptide and receptor may have role in diabetes 3Double trouble: Bacterial super-infection after the flu 2Potential of dairy-based package wraps outlined 2
Request Info...
2-min, single-step add-mix-measure assay for luciferase expression and HTS in mammalian cells. Linear detection range: 2 fg to 46 ng luciferase....
Trop-2 Purified Anti-Human clone 162-46, Isotype Mouse IgG 1 , 100 µg Consult technical datasheet for details....
... to Sf-900 II SFM.Sf21 ... from Spodoptera frugiperda (Fall ... (1). The Sf21 cells ... suspension culture in Sf-900 ...
Biology Products: